Hua’s China Deal With Bayer For Novel Oral Diabetes Drug Collapses

Hua Medicine has decided to withdraw from a commercialization partnership with Bayer on HuaTangNing (dorzagliatin) in China. (Shutterstock)

More from Deals

More from Scrip